Page 7 - ABSTRAKTI SDIR3
P. 7
CONTENT
PROGRAMME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I
LECTURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
ROUND TABLE: PRECISION MEDICINE IN ONCOLOGY:
CURRENT PERSPECTIVE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Somatic mutations testing in clinical practice: Serbian experience. . . . . . . . . . . . . . . 1
Clinical significance of epigenetic alterations in cancer. . . . . . . . . . . . . . . . . . . . . . . . . 2
The liquid biopsy in lung cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Immunotherapy in the precision medicine era: Focus on melanoma . . . . . . . . . . . . . 5
ROUND TABLE: RISING KNOWLEDGE IN MOLECULAR GENETICS OF
HEREDITARY BREAST AND OVARIAN CANCER IN THE ERA OF
NEXT GENERATION SEQUENCING . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Homologous recombination repair deficiency in ovarian cancer. . . . . . . . . . . . . . . . . 7
Detection of germline mutations in genes associated with hereditary breast and
ovarian cancer syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Significance of BRCA1 and BRCA2 genes in the era of gene-panel testing for
hereditary disease: Experience from Serbia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
CONTENT ROUND TABLE: CURRENT RESEARCH IN RADIOBIOLOGY . . . . . . . . . . . . . . . . .11
Biological mechanisms of radiation-induced cardiovascular disease studied by
proteomic analysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11
Prediction of individual radiosensitivity: Yes we can! . . . . . . . . . . . . . . . . . . . . . . . . . 12
SDIR - 3 MicroRNAs as novel factors in guiding for personalized radiotherapy . . . . . . . . . . . 12
Cytokine profiles for prediction of individual radiosensitivity . . . . . . . . . . . . . . . . . . 14
Acute and late genitourinary toxicity after 3D conformal radiotherapy for localized
prostate cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
